NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| HDFC Small Cap Fund | 7.04% |
| DSP Healthcare Fund | 1.60% |
| Polunin Emerging Markets Small Cap Fund, LLC | 1.58% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.06% |
| Document | Date |
|---|---|
| Quarterly results · Q1 FY27 UNICHEM LABORATORIES LIMITED – Q1 FY2026-27 SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY2027): ₹632.62 crores vs ₹575.12 c | 2026-08-11 |
| Annual report FY2026 UNICHEM LABORATORIES LIMITED – ANNUAL REPORT 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total Income (Standalone): ₹1,776.53 crores (FY | 2026-07-03 |
| Quarterly results · Q4 FY26 UNICHEM LABORATORIES LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: ₹2,201.85 crores (vs ₹2,110.97 crores in FY | 2026-05-22 |
| Quarterly results · Q3 FY26 UNICHEM LABORATORIES LIMITED – FINANCIAL SUMMARY Q3 & 9M FY2025-26 (Nine Months Ended December 31, 2025) --- HEADLINE NUMBERS CONSOLIDATED RESULTS | 2026-02-05 |
| Quarterly results · Q2 FY26 DOCUMENT SUMMARY: UNICHEM LABORATORIES LIMITED HEADLINE NUMBERS • Reporting Period: Q2 & H1 FY2025-26 ended 30th September 2025 • Financial Statemen | 2025-11-11 |
| Quarterly results · Q1 FY26 UNICHEM LABORATORIES LIMITED – Q1 FY2025-26 SUMMARY HEADLINE NUMBERS • Consolidated Revenue from Operations (Q1 FY26): ₹526.60 crores vs ₹587.18 cro | 2025-08-04 |
| Annual report FY2025 | 2025-07-04 |
| Quarterly results | 2025-02-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Unichem Laboratories Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.